|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2001-10-22
|
|
pubmed:abstractText |
Tumor necrosis factor alpha (TNFalpha) is a proinflammatory cytokine involved in the pathogenesis of Sjögren's syndrome (SS), and blockade of TNFalpha may reduce the activity of the disease. The purpose of this study was to evaluate the safety and potential efficacy of infliximab, a chimeric human-mouse anti-TNFalpha monoclonal antibody, in patients with active primary SS.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
44
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2371-5
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11665979-Adult,
pubmed-meshheading:11665979-Aged,
pubmed-meshheading:11665979-Antibodies, Monoclonal,
pubmed-meshheading:11665979-Female,
pubmed-meshheading:11665979-Humans,
pubmed-meshheading:11665979-Male,
pubmed-meshheading:11665979-Middle Aged,
pubmed-meshheading:11665979-Pilot Projects,
pubmed-meshheading:11665979-Sjogren's Syndrome,
pubmed-meshheading:11665979-Treatment Outcome,
pubmed-meshheading:11665979-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Infliximab in patients with primary Sjögren's syndrome: a pilot study.
|
|
pubmed:affiliation |
Department of Rheumatology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium. ssteinfe@ulb.ac.be
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
